• Vasomedical (Westbury, New York) reported that three presentations were given highlighting the benefits of external counterpulsation (EECP) therapy in patients with heart failure at the 10th annual Heart Failure Society of America Scientific (HFSA) meeting held in Seattle, Sept. 10-13: Investigators at the Escorts Heart Institute and Research Centre (New Delhi, India) presented data demonstrating that heart failure patients could double their exercise capacity following a course of EECP therapy and maintain the benefit at one-year follow-up. Susan F. Neill, Citrus Cardiology Consultants (Inverness, Florida) and Michael McIvor, MD,St. Petersburg Heart Center (St. Petersburg, Florida) presented data from 53 adult patients with systolic heart failure.William Lawson, MD, University of Stony Brook Medical Center (Stony Brook, New York) presented data from the International EECP Patient Registry demonstrating that EECP therapy is equally effective in diabetic and non-diabetic patients suffering from angina and heart failure. EECP therapy is typically given in a doctor’s office or outpatient clinic in 35 one-hour sessions over four to seven weeks. Vasomedical develops EECP external counterpulsation systems to treat cardiovascular diseases.

No Comments